| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.37 | 6e-12 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.32 | 1e-09 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.34 | 1e-09 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | -0.21 | 2e-08 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.22 | 3e-08 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.33 | 9e-08 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.28 | 2e-07 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.33 | 3e-07 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.2 | 7e-07 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.18 | 8e-07 |